EARS

Altamira Therapeutics Ltd. (EARS) | Rumor.io

Altamira Therapeutics

EARS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about EARS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 21

$EARS has potential for a breakout due to a favorable setup and a low float, with a possible run to $4 or higher if buying volume returns.
The stock's higher lows on the daily chart make it an attractive candidate for a swing trade.
$EARS is considered a popular stock with a low float of 12M, and a recent announcement of advancement in a leukemia test could lead to increased buying interest.

Generated by AI

Sentiment

Of the messages about EARS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100%
Bearish	—	—	—	0%

Bullish· Jun 3

$EARS stock rockets +7.63% after announcing the acquisition of Trasir Therapeutics, a privately held Florida-based company.
The acquisition of Trasir Therapeutics and plans for strategic repositioning are expected to drive growth for Auris Medical, with the stock soaring 10% as a result.
The chart for $EARS is setting up for potential volume, with the stock up 19.24% on 233,574 volume and trading at $4.40.

Bearish· Aug 18

$EARS's earnings report was disappointing, leading to a significant stock price drop.
The company's tinnitus treatment trial failed to meet its primary efficacy endpoints, causing a major decline in the stock price.
$EARS is facing financial difficulties, with a high likelihood of running out of cash within the next 18 months due to its recent debt addition and failed trial.

Generated by AI

Topics

Of the messages about EARS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	46.15%
Announcements	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	53.85%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Jun 3

Altamira Therapeutics Ltd. (EARS) has acquired RNA therapeutics company Trasir Therapeutics, marking a strategic repositioning for the biotech firm.
The acquisition aims to leverage Trasir's technology for safely and efficiently delivering RNA therapies to tissues beyond the liver.
EARS shares have risen by up to 12.7% following the announcement, with the company pivoting away from hearing disorder drugs and towards RNA-based medicines.

Generated by AI

Community

Of the messages about EARS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Regulars· Jun 21

Regular investors are watching for a potential breakout and testing of resistance around $4.
The larger time frame context is considered favorable for long positions in EARS.
Volume and price movement are notable, with EARS up 10.57% on 380,719 shares traded.

Newcomers· Jun 21

$EARS is considered a popular stock with a low float, which could contribute to its potential for a breakout.
The daily chart of $EARS shows higher lows, making it an attractive setup for a potential swing.
The advancement in leukemia test PR announced by $EARS is seen as a positive development, with some traders expecting a possible run to $4 or higher if buying volume returns.

Generated by AI

Also Discussed

Investors talking about EARS also mention

#	Name	Attention
1	AB Corporate Bond ETFEYEG	0%0
2	CorMedix Inc.CRMD	0%+0
3	MOSY - MoSys, Inc.	——
4	Top Ships Inc.TOPS	0%+0
5	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
6	Oragenics Inc.OGEN	0%0
7	CYTO - Altamira Therapeutics Ltd.	——
8	NVCN - Neovasc Inc.	——
9	RWLK - ReWalk Robotics Ltd.	——
10	TTNP - Titan Pharmaceuticals, Inc.	——